抗磷脂抗体患者表型识别:大型队列聚类分析
该研究对2006—2018年门诊确诊aPL阳性的486例患者(403例女性,年龄41.7岁)行多重对应分析后的层次聚类分析,识别出5个临床-实验室表型亚组。第1组以血栓事件为主(65.3%为静脉血栓),三项aPL阳性率最高(34.7%);第2组均为确诊SLE且抗dsDNA阳性率最高(91.7%);第3组为79例妊娠不良结局女性,三项阳性率3.8%,显著低于第1组;第4组41.8%符合APS、血小板减少达41.8%且无抗dsDNA抗体;第5组为94例无症状aPL携带者。作者认为第4组可能代表介于纯原发性APS与明确SLE之间的过渡状态。
要点
- aPL阳性患者可聚为5个表型亚组,涵盖血栓型、SLE型、妊娠型、过渡型及无症状携带型。
- 三项aPL阳性在第1组最高(34.7%),第3组妊娠不良结局者仅3.8%,两组差异P<0.01。
- 第4组血栓风险低于原发性APS,但ANA与血细胞减少(尤其血小板减少41.8%)更突出。
核心结论
- aPL阳性患者存在5种可区分的临床-实验室表型,其中第4组可能是纯原发性APS与明确SLE之间的过渡状态,血栓风险较低但ANA及血细胞减少更常见。
研究设计与样本
- 对2006—2018年就诊于门诊、确诊aPL阳性的486例患者(403例女性,年龄41.7岁)行基于多重对应分析的层次聚类分析。
主要发现
- 第1组150例以血栓事件为主,65.3%为静脉血栓,三项aPL阳性率34.7%为各组最高。
- 第2组91例均确诊SLE,抗dsDNA阳性率91.7%为最高。
- 第3组79例女性有妊娠不良结局,三项阳性率3.8%,显著低于第1组的34.7%(P<0.01)。
- 第4组67例中28例(41.8%)符合APS,血栓事件占23.9%,血细胞减少率最高,血小板减少达41.8%且无抗dsDNA抗体。
- 第5组94例为无症状aPL携带者。
关键数值与推荐
- 三项aPL阳性率:第1组34.7% vs 第3组3.8%,P<0.01。
- 第4组:APS占41.8%,血栓事件23.9%,血小板减少41.8%,无抗dsDNA抗体。
临床怎么用
- 对aPL阳性者可按血栓、SLE、妊娠不良结局、血细胞减少及无症状携带进行表型分层,辅助风险评估与随访。
- 对以血小板减少和ANA阳性为主、无抗dsDNA且血栓风险较低的第4类患者,需警惕其介于原发性APS与SLE之间的过渡性质。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify the aggregation of patients with aPL into different subgroups sharing common features in terms of clinical and laboratory phenotypes. METHODS: We applied a hierarchical cluster analysis from the multiple correspondence analysis to determine subgroups of patients according to clinical and laboratory characteristics in a cohort of subjects with confirmed aPL positivity who presented to our outpatient clinics from 2006 to 2018. RESULTS: A total of 486 patients [403 women; age 41.7 years (26)] were included, resulting in five clusters. Cluster 1 (n= 150) presented with thrombotic events (65.3% with venous thrombosis), with triple aPL positivity found in 34.7% of them (the highest rate among the different clusters). All the patients from cluster 2 (n = 91) had a confirmed diagnosis of SLE and the highest rate of anti-dsDNA positivity (91.7%). Cluster 3 included 79 women with pregnancy morbidity. Triple positivity was present in 3.8%, significantly lower when compared with Cluster 1 (34.7% versus 3.8%, P <0.01). Cluster 4 included 67 patients, 28 (41.8%) of whom with APS. Thrombotic events were observed in 23.9% patients. Cluster 4 had the highest rate of cytopenia, with thrombocytopenia as high 41.8% with no anti-dsDNA antibodies. Cluster 5 included 94 asymptomatic aPL carriers. CONCLUSION: While clusters 1, 2, 3 and 5 corresponded to well-known entities, cluster 4 might represent a bridging condition between pure primary APS and defined SLE, with lower thrombotic risk when compared with primary APS but higher general features such as ANA and cytopenia (mainly thrombocytopenia).
引用
- Sciascia S, Radin M, Cecchi I, et al. Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. Rheumatology (Oxford). 2021. PMID: 31840749. doi:10.1093/rheumatology/kez596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。